Skip to content

King Pharmaceuticals KG General Liability — Year 7

Other product segments

European Hospital Liability
7%
Commercial Auto Liability
5.2%
All other lines
1.2%
International
0.8%

Similar metrics at other companies

CNA Financial logo
CNAGeneral Liability — Year 7
8.4%+1.3pp
Old Republic International logo
ORIGeneral Liability — Year 7
6.5%+0.7pp
The Hartford Financial Services Group logo
HIGGeneral Liability — 7th Year
9.6%+0.5pp
CNA Financial logo
CNAGeneral Liability — Year 6
9.8%+0.6pp
CNA Financial logo
CNAGeneral Liability — Year 1
3.4%0.0pp
CNA Financial logo
CNAGeneral Liability — Year 8
5.4%-0.3pp

Other financials

Income statement

See full
Revenue$10.2M+1,112%
Net income-$7.4M-1,786%
EPS (diluted)-$0.96-586%

Balance sheet

See full
Cash & equivalents$62.2M+1,724%
Total debt$176.7M
Total equity$121.4M+2,773%
Total assets$964.2M

Cash flow

See full
Operating cash flow-$15.1M-1,628%

Valuation

See full
Market cap$70.42M-67.6%
Enterprise value$184.93M-50.0%
P/E1.2×
P/S1.6×-24.3×

Profitability

See full
Net margin131.5%

Returns & leverage

See full
Return on equity90.8%
Debt / equity1.5×

Where this comes from

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ShortdurationInsuranceContractsHistoricalClaimsDurationYearSeven.

The official record: King Pharmaceuticals’s 10-K, filed March 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about King Pharmaceuticals's general liability — year 7.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is King Pharmaceuticals's general liability — year 7?
King Pharmaceuticals (KG) reported general liability — year 7 of 8.3% in Q4 2025.
What does general liability — year 7 mean?
Represents the total revenue or financial activity generated by the General Liability insurance segment during the seventh year of the reporting period. This data point helps investors evaluate the long-term trajectory and competitive positioning of the firm's general liability product line.